^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

CDO1 (Cysteine Dioxygenase Type 1)

i
Other names: CDO1, Cysteine Dioxygenase Type 1, Cysteine Dioxygenase, Type I, CDO-I, Cysteine Dioxygenase Type I, CDO
Associations
Trials
27d
Utility and clinical effectiveness of liquid biopsy-based DNA methylation testing in early tumor screening and diagnosis, emphasizing older adult populations: a systematic review and meta-analysis. (PubMed, Front Oncol)
CDO1 promoter methylation detection in liquid biopsies shows robust diagnostic accuracy for lung cancer, with performance characteristics supporting its potential clinical utility, particularly for older populations who face barriers to conventional screening. The consistency across diverse specimen types and populations underscores its promise as a minimally invasive screening tool.
Retrospective data • Review • Journal • Liquid biopsy
|
CDO1 (Cysteine Dioxygenase Type 1)
27d
Clinical Validation of DNA Methylation Detection in Cervical Exfoliated Cells for Endometrial Cancer in Women with Suspected Lesions. (PubMed, Diagnostics (Basel))
The combination with TVS further enhances sensitivity and NPV, offering a simple and non-invasive triage strategy for patients with suspected endometrial lesions. This study was registered in China Clinical Trial Registry (ChiCTR2200055991) on 30 January 2023.
Journal
|
CDO1 (Cysteine Dioxygenase Type 1) • CELF4 (CUGBP Elav-Like Family Member 4)
2ms
A DNA methylation assay (MPap) using self-collected tampon versus cytology collection swab for endometrial cancer detection. (PubMed, Int J Gynaecol Obstet)
Our data inferred the potential of the MPap test in early detection of EC using vaginal secretion collected by an intravaginal self-collected tampon.
Journal
|
CDO1 (Cysteine Dioxygenase Type 1)
4ms
Clinical utility impact of DNA-based cytology using droplet digital methylation-specific PCR in gastric cancer. (PubMed, Gastric Cancer)
ddMSP-based detection of CDO1 methylation provides a sensitive and specific method for identifying micrometastatic peritoneal spread in GC. This DNA-based approach may serve as a valuable prognostic biomarker and contribute to improved perioperative management in gastric cancer.
Journal
|
CDO1 (Cysteine Dioxygenase Type 1)
5ms
Diagnostic Value of CDO1 Promoter Methylation in Lung Cancer via Liquid Biopsy: A Systematic Review and Meta-Analysis. (PubMed, Front Biosci (Landmark Ed))
The detection of CDO1 promoter methylation in biofluids represents a promising tool for the early diagnosis of lung cancer. Future studies should focus on improving detection methodologies and investigating combinational strategies with high accuracy.
Clinical • Retrospective data • Review • Journal • Liquid biopsy
|
CDO1 (Cysteine Dioxygenase Type 1)
7ms
Exploring the Role of CDO1 in Breast Cancer: Insights into Tumor Biology and Therapeutic Potential. (PubMed, Ann Surg Oncol)
Our findings establish CDO1 as a significant modulator of BC behavior and highlight its potential as a biomarker for prognosis. Further research is warranted to elucidate the underlying mechanisms and explore the therapeutic implications of targeting CDO1 in TNBC.
Journal
|
ADAMTS1 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1) • CDO1 (Cysteine Dioxygenase Type 1)
9ms
Taurine from tumour niche drives glycolysis to promote leukaemogenesis. (PubMed, Nature)
Consistent with elevated TAUT expression in venetoclax-resistant AML, TAUT inhibition synergizes with venetoclax to block the growth of primary human AML cells. Mechanistically, our multiomic approaches indicate that the loss of taurine uptake inhibits RAG-GTP dependent mTOR activation and downstream glycolysis. Collectively, our work establishes the temporal landscape of stromal signals during leukaemia progression and identifies taurine as a key regulator of myeloid malignancies.
Journal
|
CDO1 (Cysteine Dioxygenase Type 1)
|
Venclexta (venetoclax)
10ms
CDO1 phosphorylation is required for IL-6-induced tumor cell proliferation through governing cysteine availability. (PubMed, Cell Commun Signal)
Further, AKT1-mediated CDO1 T89 phosphorylation is required for IL-6-elicited oral squamous cell carcinoma (OSCC) growth, and is associated with the progression of OSCC development. The present data discover a new mechanism by which AKT1-mediated CDO1 T89 phosphorylation governs cysteine oxidation to support OSCC growth, thereby highlighting its value as a potential anti-tumor target.
Journal
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • IL6 (Interleukin 6) • CDO1 (Cysteine Dioxygenase Type 1)
10ms
DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding. (PubMed, Int J Gynecol Cancer)
In premenopausal women with abnormal uterine bleeding, the clinical efficacy of DNA (CDO1m/CELF4m) methylation detection in exfoliated cervical cells for endometrial cancer screening was better than that of other noninvasive clinical indicators. In addition, dual gene methylation combined with BMI or endometrial thickness was a good predictor of endometrial cancer screening.
Journal
|
CDO1 (Cysteine Dioxygenase Type 1) • CELF4 (CUGBP Elav-Like Family Member 4)
over1year
Integration of epigenomic and transcriptomic profiling uncovers EZH2 target genes linked to cysteine metabolism in hepatocellular carcinoma. (PubMed, Cell Death Dis)
Treatment with the EZH2 inhibitor tazemetostat restored expression of genes involved in cysteine-methionine metabolism and lipid homeostasis, while suppressing angiogenesis and oxidative stress-related genes...Functionally, EZH2 inhibition dose-dependently reduced cell viability and increased lipid peroxidation in HCC cells. Our findings reveal a novel epigenetic mechanism controlling lipid peroxidation and ferroptosis susceptibility in HCC, providing a rationale for exploring EZH2-targeted therapies in this malignancy.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • SLC7A11 (Solute Carrier Family 7 Member 11) • AIFM2 (Apoptosis Inducing Factor Mitochondria Associated 2) • CDO1 (Cysteine Dioxygenase Type 1)
|
EZH2 overexpression
|
Tazverik (tazemetostat)
over1year
Combination of circulating tumor cells, lncRNAs and DNA methylation for the diagnosis of endometrial carcinoma. (PubMed, Oncol Lett)
The positive rates of the methylated genes CDO1 and CELF4 were 20% (7/35) and 5.71% (2/35), and the P-values of the comparisons between the EC and NO-EC groups were 0.1748 and 0.5004, respectively; the AUC values were 0.6000 and 0.5286. Furthermore, the combination of CTCs, and lncRNAs RP4-616B8.5, RP11-389G6.3 and CTD-2377D24.6 exhibited high performance in the detection of EC (AUC=0.9375).
Journal • Circulating tumor cells • Epigenetic controller • Tumor cell
|
CDO1 (Cysteine Dioxygenase Type 1) • CELF4 (CUGBP Elav-Like Family Member 4)
over1year
LncRNA FAM83H-AS1 inhibits ferroptosis of endometrial cancer by promoting DNMT1-mediated CDO1 promoter hypermethylation. (PubMed, J Biol Chem)
Cells were incubated with erastin (the ferroptosis activator)...CDO1 knockdown or FAM83H-AS1 overexpression promoted EC tumor growth in vivo. LncRNA FAM83H-AS1 inhibited ferroptosis in EC by recruiting DNMT1 to increase CDO1 promoter methylation level and inhibit its expression.
Journal
|
DNMT1 (DNA methyltransferase 1) • CDO1 (Cysteine Dioxygenase Type 1)
|
erastin